| Project/Area Number |
23791694
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Anesthesiology/Resuscitation studies
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
FUSEYA Satoshi 信州大学, 医学部附属病院, 特任研究員 (00588197)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 骨がん痛 / 4 級アミン局所麻酔薬 / TRPV1 / ＱＸ－３１４ / ＴＲＰＶ１ / 骨がん疼痛 |
|---|
| Research Abstract |
The aim of this study was to examine effects and the mechanisms of QX-314 for bone cancer pain. An animal model of bone cancer pain was produced by implantation of osteosarcoma cells into the mouse femur. We examined the effects of QX-314 for bone cancer-induced pain-related behaviors. Systemic administration of QX-314 selectively inhibited ongoing pain-related behavior but not movement-evoked pain-related behaviors in sarcoma-implanted mice. QX-314 inhibited increase in p-CREB expression in TRPV1-positive, but not TRPV1-negative, DRG neurons in sarcoma-implanted mice. Selective ablation of TRPV1-positive afferents inhibited ongoing pain-related behavior but not movement-evoked pain-related behaviors, as did administration of QX-314. Our results indicate that QX-314 selectively inhibits TRPV1-positive afferents, reducing ongoing pain but not movement-evoked pain in bone cancer pain.
|
